Physician profile
Thomas Mitchell Gallagher
NPI 1043604945
$1,456.49
in general payments reported to CMS, 2019-2025
14 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $129 · 2022: $303 · 2023: $235 · 2024: $321 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $627.76 | 2023-2025 | |
| Allergan, INC. | $257.97 | 2022 | |
| Motiva USA, LLC | $185.30 | 2025 | |
| Hydrofera LLC | $129.44 | 2021 | |
| Acera Surgical, INC. | $68.11 | 2025 | Restrata Wound Matrix |
| Merck Sharp & Dohme LLC | $38.11 | 2022-2025 | Bridion |
| Solventum Corporation | $31.88 | 2024 | Activ.A.C., Prevena, V.A.C.Instill |
| Tela Bio, INC. | $30.20 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Polynovo North America LLC | $16.19 | 2025 | Novosorb Btm |
| Organogenesis INC. | $15.53 | 2025 | Cygnus Dual |
| Integra Lifesciences Corporation | $15.42 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Medtronic, INC. | $14.95 | 2023 | V-Loc 180 |
| Mentor Worldwide LLC | $12.89 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $12.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.